Indication: For the treatment of mildly to moderately active ulcerative colitis
Pharmacology: Balsalazide is a prodrug that is enzymatically cleaved in the colon to produce mesalamine (5-aminosalicylic acid), an anti inflammatory drug indicated for the treatment of mildly to moderately active ulcerative colitis. Balsalazide disodium is delivered intact to the colon where it is cleaved by bacterial azoreduction to release equimolar quantities of mesalamine, which is the therapeutically active portion of the molecule, and 4-aminobenzoyl-(beta)-alanine.
Mechanism Of Action: The mechanism of action of 5-aminosalicylic acid is unknown, but appears to be topical rather than systemic. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes and hydroxyeicosatetraenoic acids, is increased in patients with chronic inflammatory bowel disease, and it is possible that 5-aminosalicylic acid diminishes inflammation by blocking production of arachidonic acid metabolites in the colon.
Interactions:
DrugBank: Interactions for Balsalazide
Interactions for Balsalazide:
No drug interaction studies have been conducted for COLAZAL ô, however the use of orally administered
antibiotics could, theoretically, interfere with the release of mesalamine in the colon.
Chemical IUPAC Name: 5-[4-(2-carboxyethylcarbamoyl)phenyl]azo-2-hydroxy-benzoicacid
Salix Pharmaceuticals Development Update; XIFAXAN(R) Trials ...Jan 11, 2006 Business Wire (press release), Additionally, initial subjects have been enrolled and dosed in a late-stage trial designed to evaluate an 1100 mg tablet formulation of COLAZAL(R) for the ...
Home
Copyright phasechange.org 2006.
All Rights Reserved.
